Kaleido Biosciences, Inc. (KLDO) News
Filter KLDO News Items
KLDO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KLDO News Highlights
- KLDO's 30 day story count now stands at 10.
- Over the past 24 days, the trend for KLDO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BEAT, BPMC and GBT are the most mentioned tickers in articles about KLDO.
Latest KLDO News From Around the Web
Below are the latest news stories about Kaleido Biosciences Inc that investors may wish to consider to help them evaluate KLDO as an investment opportunity.
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/YGlobal Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates. |
Kaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseKaleido Biosciences, Inc. (KLDO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine. |
Is a Beat Likely for Perrigo (PRGO) This Earnings Season?Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter. |
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top MarkBlueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down. |
10 Cheap Pharmaceutical Stocks For 2022In this article, we discuss 10 cheap pharmaceutical stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Pharmaceutical Stocks For 2022. The pharma industry is in the midst of a fundamental transformation as disruptive technologies like artificial intelligence, machine learning, and natural language processing become […] |
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTInvaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. |
Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 WeeksKaleido Biosciences, Inc. (KLDO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Kaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD FoundationIn a 8-K filing, Kaleido Biosciences (NASDAQ:KLDO) announced that it has decided to halt work on a planned Phase 2 study of KB109 in patients with chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and... |
Kaleido Halts Upcoming Phase 2 COPD Trial, Piper Sandler Cuts Price TargetKaleido Biosciences Inc (NASDAQ: KLDO) halted work on a planned phase 2 trial in chronic obstructive pulmonary disease (COPD) and terminated its agreement with the COPD Foundation to realign resources. The Company had announced the COPD agreement in August 2021. The Phase 2 asset, dubbed KB109, was slated to enter the mid-stage study in 1H 2022, the company said during its Q3 FY21 earnings release. The Company had also tested KB109 in patients with mild-to-moderate COVID-19. But Kaleido had not |